Cytokinetics (CYTK) Gains from Investment Securities (2016 - 2025)
Historic Gains from Investment Securities for Cytokinetics (CYTK) over the last 13 years, with Q4 2024 value amounting to $1.2 million.
- Cytokinetics' Gains from Investment Securities changed N/A to $1.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $19.6 million, marking a year-over-year increase of 8665.97%. This contributed to the annual value of $19.6 million for FY2024, which is 6664.36% up from last year.
- According to the latest figures from Q4 2024, Cytokinetics' Gains from Investment Securities is $1.2 million.
- In the past 5 years, Cytokinetics' Gains from Investment Securities registered a high of $77.9 million during Q1 2021, and its lowest value of -$2.8 million during Q4 2021.
- Over the past 5 years, Cytokinetics' median Gains from Investment Securities value was $3.3 million (recorded in 2021), while the average stood at $12.4 million.
- Over the last 5 years, Cytokinetics' Gains from Investment Securities had its largest YoY gain of 694222.42% in 2021, and its largest YoY loss of 34482.16% in 2021.
- Cytokinetics' Gains from Investment Securities (Quarter) stood at $1.1 million in 2020, then crashed by 344.82% to -$2.8 million in 2021, then skyrocketed by 146.29% to $1.3 million in 2022, then surged by 707.76% to $10.5 million in 2023, then plummeted by 88.76% to $1.2 million in 2024.
- Its Gains from Investment Securities stands at $1.2 million for Q4 2024, versus $18.4 million for Q1 2024 and $10.5 million for Q1 2023.